Introduction
CJ Biomaterials is a biopolymer and bio-based chemicals company within the CJ CheilJedang/CJ BIO group that develops and manufactures polyhydroxyalkanoates (PHAs), a family of bio-based, biodegradable polyesters produced by microbial fermentation. The company is headquartered in Woburn, Massachusetts, with additional offices and manufacturing capacity supporting global commercialization, and it markets its PHA portfolio under the PHACT™ brand.
In the plastics industry, CJ Biomaterials is positioned as a specialist in sustainable polymer alternatives rather than a conventional petrochemical resin producer. Its materials are designed to address applications where end-of-life performance is important, including flexible and rigid packaging, food serviceware, 3D printing, agricultural films, coatings, personal care, healthcare, nonwovens, and paper coatings. The company emphasizes PHAs that can be tailored from amorphous to semi-crystalline and crystalline structures, allowing different balances of flexibility, stiffness, and biodegradation behavior.
CJ Biomaterials’ current business builds on a longer CJ BIO biotechnology history that began in food fermentation, later expanding into biomaterials. According to the company, its PHA platform was advanced through the acquisition of Metabolix technology in 2016, followed by the formal launch of the CJ Biomaterials business in 2022 and the startup of a PHA production facility in Pasuruan, Indonesia. The company presents its technology as a route to replace some fossil-fuel-based plastics with materials that are bio-based, compostable, and biodegradable in soil and marine environments.
History and Development
CJ Biomaterials traces its technical roots to CJ BIO’s broader fermentation platform, which began in 1964 with monosodium glutamate production and expanded into amino acids, nucleotides, and other fermentation-derived ingredients. The biomaterials business itself was later developed as part of CJ Group’s biotechnology strategy, which the company says was inaugurated in 2010.
A major development occurred in 2016, when CJ CheilJedang acquired Metabolix and its PHA technology. CJ later continued industrialization work to make PHA production available at commercial scale.
The CJ Biomaterials business was launched in 2022, and the company says that shortly afterward it inaugurated a new PHA production facility in Pasuruan, Indonesia, while introducing its first product, PHACT™ A1000P. This product was positioned as an amorphous PHA with certifications and claims related to industrial compostability, soil biodegradation, marine biodegradation, and home compostability.
Business Operations and Corporate Context
CJ Biomaterials operates as part of the wider CJ BIO division and ultimately the South Korea-based CJ Group. CJ BIO also has activities in animal nutrition, human nutrition, plant nutrition, enzymes, and biomaterials, with manufacturing operations across multiple countries.
In China, the business is associated with 希杰（上海）商贸有限公司 and the broader CJ China organization, which has promoted PHACT materials to Chinese industrial customers and brand owners. Chinese corporate and exhibition materials indicate that the company is active in domestic marketing, sales, and application development for biodegradable plastic solutions.
Products and Technologies
CJ Biomaterials’ core product family is PHACT™, its brand for polyhydroxyalkanoate biopolymers. PHAs are produced through microbial fermentation of renewable feedstocks, including plant-derived sugars such as sugar cane, tapioca, corn, and cellulosic biomass.
The company says it can produce a customized range of polymer structures, including:
Technically, this matters because polymer structure affects processing window, stiffness, flexibility, and degradation behavior. CJ Biomaterials states that its PHA materials can be used either as neat resins or as modifiers in compounds to increase bio-based content, improve functional properties, and accelerate biodegradation in finished products.
The company identifies several standard processing routes for PHA-inclusive materials:
- Film
- Thermoforming
- Injection molding
- Fibers and nonwovens
- Extrusion
- Paper coatings
Public company materials also describe PHAs as useful in formulations that require home compostability, industrial compostability, and biodegradation in soil and marine environments. The company presents these properties as part of its strategy to replace select fossil-based plastics and chemicals with more circular alternatives.
Applications and End Markets
CJ Biomaterials focuses on applications where sustainability claims must be balanced against manufacturing performance and process compatibility. The company highlights use cases in:
- Flexible and rigid packaging
- Food serviceware
- Beauty and cosmetic containers
- 3D printing
- Agricultural films
- Coatings and adhesives
- Personal care
- Healthcare
- Paper coatings
- Nonwovens
In China, the company’s marketing materials specifically reference opportunities in cosmetics packaging, consumer goods, food serviceware, flexible packaging, labels, paper-coating systems, fibers, and nonwovens. This indicates a strategy centered on brand-owner-led adoption in packaging and adjacent consumer-product categories.
Global Presence and Market Position
CJ Biomaterials describes itself as a global manufacturer with offices in Woburn, Massachusetts, Frankfurt, Germany, and operations linked to CJ’s wider international manufacturing network. The company also states that it has manufacturing facilities strategically positioned to support global markets, with its Indonesian facility identified as the site for large-scale amorphous PHA production.
Within the PHA segment, CJ Biomaterials positions itself as a major commercializer of the technology and says it is the world’s largest producer of amorphous PHA at its Pasuruan facility. Because public market data on PHA capacity is limited and the sector remains relatively small compared with mainstream polyolefins and PET, that claim is best understood as the company’s self-described market position rather than an independently verified industry ranking.
Sustainability and Environmental Initiatives
Sustainability is central to CJ Biomaterials’ corporate identity. The company frames its technology as an answer to fossil-fuel-based plastics and plastic waste, emphasizing that its materials are bio-based and designed for compostability and biodegradation under selected conditions.
The company also states that its PHACT™ materials are certified by third parties as biobased, compostable in home and commercial conditions, and biodegradable in marine and soil environments. In addition, CJ Biomaterials presents its products as alternatives that do not create persistent microplastics, aligning the company with a broader industry search for materials that fit emerging circular-economy and extended-producer-responsibility goals.
At the corporate level, CJ’s broader bio business has described efforts toward lower-impact manufacturing and value-added co-products, while CJ Biomaterials presents its own mission as scaling circular material solutions across global markets.
Leadership and Corporate Governance
CJ Biomaterials operates as a business unit within a larger conglomerate structure rather than as an independent listed plastics company. Public filings and corporate materials identify the business as part of CJ CheilJedang and the CJ BIO division, which provides access to fermentation expertise, industrial infrastructure, and global commercial channels.
For the Chinese entity 希杰（上海）商贸有限公司, publicly available corporate information indicates that it was established in 2007 and has operated in trade, import/export, and related support functions for the group’s business lines in China. Corporate affiliation data also indicate that the Shanghai entity is connected to CJ’s wider bio and food businesses rather than being a standalone polymer manufacturer.
Innovations and Future Outlook
CJ Biomaterials’ innovation strategy centers on improving the performance, processability, and commercial scale of PHA materials. The company emphasizes four internal capability areas: bioscience, chemical engineering, materials innovation, and application development.
A notable development is the company’s collaboration with Matmerize in 2024 to use AI-based polymer informatics for sustainable polymer design, suggesting that data-driven formulation and material discovery are becoming more important to its R&D approach. The company has also publicized application partnerships, including work in eco-beauty and packaging, indicating a strategy of co-development with downstream brands and converters.
Looking ahead, CJ Biomaterials’ prospects depend on several factors: the economics of fermentation-based polymers, scale-up of PHA manufacturing, regulatory and customer demand for compostable materials, and the ability to match fossil-based plastics on cost and processing behavior in demanding applications. Its strongest opportunities appear to lie in specialty and branded consumer applications where sustainability, biodegradability, and differentiated end-of-life performance have measurable value.
References
- •
CPS+ eMarketplace. (n.d.). CJ BIOMATERIALSCJ BIOMATERIALS. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1028050Link